Index

AAIDD. See American Association of Intellectual and Developmental Disabilities
ABA. See applied behavioral analysis
ACA. See anterior cerebral arteries
ADHD. See attention deficit hyperactivity disorder
ADL. See activities of daily living
AD. See Alzheimer’s disease
ADAM. See Americans with Disabilities Act
ADAM. See Americans with Disabilities Act Amendments Act (ADAAA)
ADD. See Attention Deficit Hyperactivity Disorder
ADDM Network. See Autism and Developmental Disabilities Monitoring Network
ADHD. See attention deficit hyperactivity disorder
AD. See activities of daily living
ADHD. See attention deficit hyperactivity disorder
ADL. See activities of daily living
adolescence. See also pediatric cancer; pediatric HIV; pediatric ischemic stroke
ADHD during, 94
HIV and, 215–216
behavioral and emotional functioning, 216
cognitive functioning, 215–216
HAND, 217–219
intellectual disability syndromes during, 73
MS in, 234–235
SBM during, 30
TBI and, behavioral and emotional outcomes with, 145
ADT. See androgen deprivation therapy
adult care, transition to with ASD, 54–55
for college and university attendance, 54
for employment, 54–55
for independent living skills, 55
in epilepsy treatment, 203
with intellectual disability syndromes, 73–74
with LD, 130
RD, 123
after pediatric TBI, 145–146
with SBM, 38
adult patients with cancer. See cancers
ADTs. See antiepileptic drugs
African Americans, SBM among, 24
age
intellectual disability syndromes by, 73–74
maternal, DS and, 65
MS and, age of onset for, 228
aging. See also adult care
HIV and, 212, 217
AIDS. See acquired immune deficiency syndrome
AIM program. See Attention Intervention and Management program
alcohol-related birth defects (ARBD), 79
alcohol-related neurodevelopmental disorder (ARND), 79
alemurzumab, 237
ALL. See acute lymphocytic leukemia
all-cause dementia, 269
Alzheimer’s disease (AD), 268, 269–271
behavioral features, 272
clinical features, 273
neuropsychological features, 272
American Association of Intellectual and Developmental Disabilities
AACIHD, 61
Americans with Disabilities Act (ADAAA), 54, 117
AML. See acute myeloid leukemia
anterior cerebral arteries (ACA), 7–10
anxiety, cancer and, 175
anticipatory guidance, 37
antiepileptic drugs (AEDs), 186, 201–202, 204
antiretroviral (ARV) treatments, 210, 220
See also combination antiretroviral therapy
anxiety, cancer and, 175
anxiety disorder, 45, 235
aphasia, 256
applied behavioral analysis (ABA), 51
behavioral features, 272
clinical features, 273
neuropsychological features, 272
Asian populations, SBM among, 24
autism spectrum disorders (ASD), 54, 117
autism treatment
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
ATN.
comorbid psychiatric disorders, 95
CD, 9, 95
MDD, 95
ODD, 9, 95
DSM-5 diagnostic criteria, 93
employment outcomes with, 94
epidemiology, 93–94
gender distribution, 94
by race, 94
epilepsy and, 192–193, 195
etiology, 107
functioning domains with, 94–95
during adolescence, 94
during childhood, 94
intervention strategies, 101–107
academic, 103
BPT, 103–104
classroom-based, 102–103
cognitive training, 106–107
organizational skills, 104–105
pharmacological, 101–102
physical activity, 107
school-based, 102–103
self-regulatory, 103
skill-based, 104
LBW/preterm birth and, 9
PAE and, 86–87
pathophysiology, 95–97
brain development, 96–97
through fMRI imaging, 96–97
heritability factors, 95–96
phenotype, 97
pediatric ischemic stroke and, 253
SBM and, 26
subtypes, 93
attention deficits
with ASD, 50
with DS, 65–66
with epilepsy, 192–193
with FASD, 84–85
iPC and, 5
LBW/preterm birth and, 5–7
with MS, 234
with pediatric, 170
with SBM, 25–26
intervention strategies, 33–34
neuropsychological evaluations of, 31
with stroke, pediatric ischemic stroke, 253
top-down abilities, 26
Attention Intervention and Management (AIM) program, 152–153
Autism and Developmental Disabilities Monitoring (ADDM) Network, 46
autism spectrum disorders (ASD)
ADHD and, 45
adult care practices, transition to, 54–55
for college and university attendance, 54
for employment, 54–55
for independent living skills, 55
under Americans with Disabilities Act, 54
anxiety disorder and, 45
clinical features, 45–46
clinical practices, 56
future research on, 57
pharmacological interventions, 55–57
clinical presentation, 47–51
attentional deficits, 50
brain development, 48
cognitive function, 49
EF deficits, 50
language skills development, 49–50
megencephaly, 48
memory impairment, 50–51
motor function impairments, 51
social interaction issues, 9–10, 47
diagnostic criteria, 45, 48–49
by CDC, 47
in DSM-5, 45, 46
with fMRI, 48
testing instruments in, 48–49
epidemiology, 46–47
ADDM Network, 46
prevalence rates, 46
intervention approaches, for children, 51–54
ABA, 51–52
Early Social Interaction Project, 53
ESDM, 52–53
NDBI, 52
PRT, 52
LBW/preterm birth and, 9–10
mood disorder and, 45
pathophysiology, 46–47
genetic factors, 46
pharmacological interventions, 55–57
Autism Treatment Network (ATN), 56
AVM. See arteriovenous malformation
Bayley Scales of Infant Development, 219–220
Behavior Rating Inventory of Executive Function (BRIEF) scores, 7
behavioral parent training (BPT), 103–104
behavioral variant Frontotemporal Dementia (bvFTD), 268, 273
behavioral features, 272
clinical features, 273
neuropsychological features, 272
specific assessment considerations, 279
biomarkers, in dementia, 269, 282
birth defects. See also spina bifida
myelomeningocele
prevalence rates for, 24
by race, 24
BPT. See behavioral parent training
brain attack, 259. See also stroke
brain development with ADHD, 96–97
with ASD, 48
with HIV, 212
LBW/preterm birth and, 4
LD and, 120
with SBM, 31
white matter development, with megencephaly, 48
Brief Repeatable Battery of Neuropsychological Tests (BRB), 236
BRIEF scores. See Behavior Rating Inventory of Executive Function scores
bvFTD. See behavioral variant Frontotemporal Dementia
cancer-related cognitive impairment (CRCI), 163–164
chrones. See also pediatric cancer
ALL, 162
intellectual functioning with, 170
AML, 162
anxiety and, 175
assessment recommendations, 177
clinical manifestations, 166–167
clinical practice implications, 168
CML, 162
CML, 162
CNS tumors, 162
surgical interventions for, 163–164
depression and, 175
diagnosis rates, 162
interventions for, 175–177
CBT, 175
future research on, 177–179
neuropsychological, 176–177
pharmacological, 175–176
liquid tumors, 162
neuroanatomical correlates, 166–167
neuropsychological functioning, 172–173
assessment tests, 172
genotype associations, 173
prevalence rates, 162
cancer (cont.)
prevention strategies, 170
solid tumors, 162
treatment factors, functioning
influenced by, 163–170
chemotherapy, 164
CRT, 163–164
eendocrine therapy, 165–168
hormonal therapy, 165–168
HSCT, 164–165
radiation therapy, 165
SES as factor in, 169
cART therapy. See combination antiretroviral therapy
CAS. See Cognitive Assessment System
CBT. See cognitive behavioral therapy
CD. See conduct disorder
Centers for Disease Control (CDC)
ASD diagnostic criteria, 47
FASD estimates, 80
intellectual disability rates, 61–62
central nervous system (CNS) tumors, 162
surgical interventions, 163
cerebral atrophy, 254
cerebral palsy (CP), 3
cerebral sinusovenous thrombosis
(CSVT), 244
ischemic stroke, 244
cerebral small vessel disease (CSVD), 247, 248, 254
cerebral vascular accident, epilepsy and, 188
chemoprotectants, 169
chemotherapy, 164
Chiari-II malformation, 25
Chicago Multiscale Depression Inventory, 262
children. See infants and children
cholesterol level management, 249
chronic lymphocytic leukemia (CLL), 162
chronic myeloid leukemia (CML), 162
chronic traumatic encephalopathy (CTE), 146–147
CIFASD. See Collaborative Initiative on Fetal Alcohol Spectrum Disorders
CIS. See clinically isolated syndrome
clinically isolated syndrome (CIS), 233
CLL. See chronic lymphocytic leukemia
CML. See chronic myeloid leukemia
CNS tumors, 162
"cocktail party syndrome," 32
Cognitive Assessment System (CAS), 31
cognitive behavioral therapy (CBT) for ADHD, 105–106
group metacognitive therapy, 105–106
individual, 105
in cancer interventions, 175
for epilepsy, 202–203
cognitive function
with ASD, 49
with FASD, 81–87
academic outcomes, 86
EF, 84–85
language skills development, 85
learning impairments, 85–86
memory impairments, 85–86
with HIV, 212–213
in adolescence, 215–216
LBW/preterm birth, 5
metacognition, 26
with MS, 234–235
in adults, 234
attention deficits, 234
in children and adolescents, 234–235
EF, 235
language skills development, 234–235
memory deficits, 234
with HIV, 213–215
with stroke, 263–263
pediatric ischemic, 257–258
with TBI, 141, 142–144
cognitive rehabilitation
for HAND, 221
for MS, 238–239
cognitive reserve, 212
Cogstate program, for pediatric cancer assessment, 178–179
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), 84
combination antiretroviral (cART) therapy, 212, 217, 220
for HAND, 220–221
Comprehensive Assessment of Spoken Language, 32
conduct disorder (CD), 9, 95
continuous performance tests (CPTs), 99–100
corticosteroids, 237
CP. See cerebral palsy
CPTs. See continuous performance tests
cranial radiation therapy (CRT), 163–164
for pediatric cancer, use limitations in, 169
CRCI. See cancer-related cognitive impairment
CRT. See cranial radiation therapy
CSVD. See cerebral small vessel disease
CSV. See cerebral sinusovenous thrombosis
CTE. See chronic traumatic encephalopathy
culture, epilepsy considerations
influenced by, 197
neuropsychological assessment of, 200
dacizumab, 237
dAI. See diffuse axonal injury
DART. See Dual Attention to Response Task
delayed onset dementia, 275
dementia
AD, 268, 269–271
behavioral features, 272
clinical features, 273
neuropsychological features, 272
all-cause, 269
assessment strategies
comprehensive, 278–279
neuropsychological, 276–277
normative considerations in, 279
screening tests, 277–278
serial, 279
specific considerations in, 279–280
test design for, 282
utility of, 282
bvFTD, 268, 273
behavioral features, 272
clinical features, 273
neuropsychological features, 272
specific assessment considerations, 279
causes of, 270
common causes of, 268
comprehensive assessment of, 278–279
definitions, 268
diagnostic criteria, 268–269
biomarkers in, 269, 282
clinical overview, 281
NCDs, 268–269
epidemiology of, 271
with epilepsy, 194–195
frontotemporal, 270
interventions for, 280–282
clinical overview, 281
non-pharmacological, 280–281
pharmacological, 280
LBD, 268, 270, 271–273
behavioral features, 272
clinical features, 273
neuropsychological features, 272
specific assessment considerations, 279–280
neuroimaging in, 277
prevention strategies, 275
risk factors, 273–274
support factors for, 275–276
for delayed onset, 275
limited, 276
from TBI, 146–147
CTE, 146–147
unsupported factors for, 276
Dementia with Lewy Bodies. See Lewy Body Disease
depression
cancer and, 175
Chicago Multiscale Depression Inventory, 262
with MS, 235
stroke and, 262
developmental MD, 121
diabetes, management of, 249
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
ADHD diagnostic criteria, 93
ASD, 45, 46
intellectual disability, 61, 63
LD diagnostic criteria, 117–119
for basic academic skills, 118
for complex academic skills, 118
IQ levels in, 118–119, 127
diet and nutrition
ketogenic, 202
stroke prevention and, 249
diffuse axonal injury (DAI), 140
diffuse TBI, 140
dimethyl fumarate, 237
Donepezil, 173–174
Down syndrome (DS), 64–66
attention deficits with, 65–66
epidemiology, 64–65
etiology, 64–65
chromosome 21 overexpression, 64–65
maternal age, 65
race and ethnicity factors, 65
language development and, 65–66
medical comorbidities, 65
motor function and, 65–66
neurobehavioral profile, 65–66
neurological basis, 66
phenotype, 65
prevalence rates, 64–65
survival prognosis, 66
DS. See Down syndrome
DSM-5. See Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
Dual Attention to Response Task (DART), 31
dyslexia. See also reading disorder
heritability of, 120
Early Social Interaction Project, 53
Early Start Denver Model (ESDM), 52–53
Education for All Handicapped Children Act (1975), 116
education services. See special education services
EF. See executive functioning
ELBW. See extremely low birth weight
employment outcomes
with ADHD, 94
with ASD, 54–55
endocrine therapy, 165–168
endoscopic third ventriculostomy with choroid plexus cauterization (ETV/CPC), 38–39
EP birth. See extremely preterm birth
epilepsy
ADHD and, 192–193, 195
in adults
cognitive manifestations, 193–195
psychoclinical features, 193–195
assessment techniques, 188
behavioral manifestations of, 192
cerebral vascular accident and, 188
in children
cognitive manifestations, 188–193
psychosocial features, 195
clinical practice implications, 205–206
cognitive manifestations of, 188–195
academic outcomes, 193
attention deficits, 192–193
EF deficits, 193
memory deficits, 193
cultural considerations across lifespan, 197
neuropsychological assessment of, 200
defined, 186
dementia with, 194–195
EF and, 193
neuropsychological assessment of, 201
ischemic stroke and, 188
longer-term outcomes with, 197
longitudinal development studies, 197
medically refractory, 192
memory functions and, 193
neuropsychological assessment of, 200–201
mental health disorders with, 202–203
neuropsychological aspects of, 189–191
neuropsychological assessment of, 199–201
cultural considerations, 200 for EF, 201
ILAE Neuropsychology Task
Force, 199–200, 204, 205–206
for intellectual functioning, 200
language skills, 200
for memory, 200–201
new-onset, 194
prevalence rates, 186–187
prevention strategies, 187
early, 187
against infection, 187
PTE, 187–188
seizures, 186
PNES, 197–199
after TBI, 187–188
treatment strategies, 201–202
with AEDs, 186, 201–202, 204
with CBT, 202–203
through ketogenic diet, 202
transition to adult care, 203
VNS, 202
ESDM. See Early Start Denver Model
ETV/CPC. See endoscopic third ventriculostomy with choroid plexus cauterization
executive functioning (EF) with ADHD, 100
with ASD, 50
BRIEF scores, 7
epilepsy and, 193
neuropsychological assessment of, 201
with FASD, 84–85
with HIV, 212–213
LBW/preterm birth and, 5–7
with MS, 235
neuroatometrical correlates of, 7
with pediatric cancer, 170
with SBM, 26–27
clinical treatment practices for, 37
intervention strategies for, 34
neuropsychological evaluations of, 31
with stroke, 257–257
pediatric ischemic stroke, 253
Expanded Disability Status Scale, 233–234
extremely low birth weight (ELBW), 2
extremely preterm (EP) birth, 2
facilitative intervention training (FIT), 106–107
families, functioning skills for, with SBM, 29–30
clinical manifestations, 29–30
interprofessional team partnering with, 36–37
intervention strategies for, 35–36
neuropsychological evaluations of, 33
SES factors, 29–30
Index

families, TBI and, psychosocial outcomes for, 145
FAS. See fetal alcohol syndrome
FASD. See fetal alcohol spectrum disorders
fatigue, with MS, 235
females. See women
fertility treatments, preterm birth rates and, 2
fetal alcohol spectrum disorders (FASD)
ARBD, 79
ARND, 79
behavioral functioning, 87
neuroanatomical correlates, 82–83
CDC estimates, 80
during childhood, 82–83
clinical care practices, 89–90
cognitive impairments, 81–87
academic outcomes, 86
EF, 84–85
language skills development, 85
learning impairments, 85–86
memory impairments, 85–86
defined, 79
diagnostic criteria, 79
epidemiology, 80
FAS, 79
pFAS, 79
interventions, 88–89
future directions for, 90
non-pharmacological, 88–89
pharmacological, 88
neuropsychological impairments, 81–87
adaptive functioning, 86–87
assessments of, 87
attentional difficulties, 84–85
CIFASD program, 84
intellectual disability, 82–84
motor function, 86
visual–spatial processing, 85
NIAAA guidelines, 79
PAE, 79, 81
ADHD and, 86–87
ND-PAE, 79–80
pathophysiology, 80
prevention strategies, 80–81
UPPSs, 81
psychopathology with, 87
psychosocial functioning, 87
fetal alcohol syndrome (FAS), 79
pFAS, 79
fingolimod, 237
FIT. See facilitative intervention training
Flair MRI, 247–248
fMRI. See functional magnetic resonance imaging
focal TBI, 140
Fragile X syndrome (FXS), 66–67
ADHD and, 66
ASD and, 66
comorbidities, 66
epidemiology, 66
etiology, 66
gender factors, 67
long-term prognosis, 67
neurobehavioral profile, 67
neurological basis, 67
phenotype, 66
prevalence, 66
frontotemporal dementia, 270
Full Scale IQ (FSIQ), 68
functional adaptation, with SBM, 30
intervention strategies for, 36
neuropsychological evaluations of, 33
functional magnetic resonance imaging (fMRI)
for ADHD, 96–97
for ASD diagnosis, 48
FXS. See Fragile X syndrome
gender. See also males; women
ADHD and, 94
FXS and, 67
long-term prognosis by, 67
MS and, 228
glatiramer acetate, 237
glucocorticoids, 168–169
goal-setting. See metacognition
Gordon Diagnostic System, 31
group metacognitive therapy, 105–106
HAND. See HIV–associated neurocognitive disorders
health-related quality of life (HRQoL) with HIV, 213, 217
with SBM, 29
hematopoietic stem cell transplant (HSCT), 164–165
hemispatial neglect, 256
hemorrhagic stroke, 244, 247
Hispanic populations, SBM among,
HIV. See human immunodeficiency virus
HIV–associated neurocognitive disorders (HAND), 211, 212
in adolescents, 217–219
in adults, 217
cART and, 220–221
in children, 217–219
cognitive rehabilitation, 221
development of, 216–217
hormonal therapy, 165–168
HRQoL. See health-related quality of life
HSCT. See hematopoietic stem cell transplant
human immunodeficiency virus (HIV). See also HIV–associated neurocognitive disorders; pediatric HIV
in adolescence, 215–216
behavioral and emotional functioning, 216
cognitive functioning, 215–216
HAND, 217–219
adults with
evidence-based guidelines, 221
HAND, 217
aging and, 212, 217
AIDS and, 210
clinical manifestation, 212–216, 222
ADLs, 213
behavioral function, 213
cognitive function, 212–213
EF, 212–213
emotional functioning, 213
motor function, 213
cognitive functioning with, 212–213
in adolescence, 215–216
in infants and children, 213–215
cognitive reserve, 212
development history for, 210
epidemiology, 211–212
UNAIDS projections, 211
HRQoL with, 213, 217
interventions for, 210–211
longitudinal development, 216–223
mood disorders with, 213
neuropsychological development, 216–223. See also HIV–associated neurocognitive disorders
assessment methods, 219–220
pathophysiology, 211–212
brain development, 212
CNS damage, 211. See also HIV–associated neurocognitive disorders
in perinatal acquisition, 211–212
prevalence rates, 211
prevention, 212
research on, 210–211
treatment strategies
ARV, 210, 220
cART, 212, 217, 220–221
evidence-based guidelines, 223
hybrid models, for LD testing, 128
hydrocephalus, 25
hypercholesterolemia, 249
hyperfracturation, 169
ICD-10. See International Classification of Diseases
IEP. See individualized education program
iFC. See intrinsic functional connectivity
ILAE Neuropsychology Task Force, 199–200, 204, 205–206
discrepancy approaches, 129
future strategies for, 130–133
hybrid models, 128
Index
291

© in this web service Cambridge University Press
www.cambridge.org
learning disabilities (LD). (cont.)
intraventricular hemorrhage (IVH), 2
intra-individual differences
model, 126–127
low achievement model, 126
regression to the mean model,
127–128
RTI model, 128
learning skills. See also academic
outcomes
with FASD, 85–86
non-verbal, 86
verbal, 85
with pediatric ischemic stroke, 253
lesions
with MS, 229
with stroke, 254
leukemias. See specific leukemias
Levy Body Disease (LBD), 268, 270,
271–273
behavioral features, 272
clinical features, 273
neuropsychological features, 272
specific assessment considerations,
279–280
liquid tumors, 162
low achievement model, 126
low birth weight (LBW)
academic outcome issues with, 7–10
prevention strategies for, 8–9
special education services, 8
ASD and, social issues as result of,
9–10
classifications, 2
decline of, 2–3
defined, 2
developmental disorders
ADHD, 9
ASD and, 9–10
diagnosis of, 11
interventions for, 11–13
personality issues, 10–13
ELBW, 2
emotional issues and, 10
epidemiology, 2–16
intellectual disability and, 63
LBW, 2
learning disabilities and, 7–10
ADHD, 9
diagnostic evaluations of, 14–15
prevention strategies, 8–9
special education services, 8
mortality rates, 3
neurodevelopmental complications,
3, 4, 14–16
attention issues, 5–7
brain development, 4
cognitive ability, 5
CP, 3
diagnostic evaluations of, 14–15
EF deficits, 5–7
IQ, 5
long-term, 4–16
PVL, 3
visuomotor skills, 7
pathophysiology, 2–16
personality issues, 10–13
corrected age evaluations, 10–11
prevalence rates for, 2
prevention strategies, 3
risk factors for, 2
WHO demographics for, 2
LP birth. See late preterm birth
MACFIMS. See Minimal Assessment
of Cognitive Function in MS
magnetic resonance imaging (MRI)
Flair, 247–248
fMRI
for ADHD, 96–97
for ASD diagnosis, 48
Major and Mild Neurocognitive
Disorders (NCDS), 268–269
major depressive disorder (MDD), 95
males
ADHD in, 94
with FXS, 67
math disorder (MD), 120–121
comorbidity with, 121
developmental, 121
social, 121
intervention strategies, 129
prevalence rates, 120–121
MD. See middle cerebral arteries
MDD. See major depressive disorder
with stroke, 254
with MS, 235
mortality rates
LBW/preterm birth, 3
SBM, 25
mosaic trisomy, 64–65
Mother-Infant Transaction Program
(MITP), 12
motor function
with ASD, 51
with DS, 65–66
with FASD, 86
with HIV, 213
with intellectual disability
syndromes, 73
LBW/preterm birth and, 7
with pediatric cancer, 170
with pediatric ischemic stroke,
252–253
with SBM, 28
intervention strategies for, 35
neuropsychological evaluations
of, 32
MP birth. See moderately preterm
birth
MRI. See magnetic resonance imaging
multiple sclerosis (MS)
clinical manifestations, 230–235
in children, 230
CIS, 233
clinical practice implications,
239
cognitive functioning, 234–235
in adults, 234
attention deficits, 234
Index

naturalizumab, 237
National Comprehensive Cancer Network (NCCN), 177
National Institute on Alcohol Abuse and Alcoholism (NIAAA),
National Joint Committee on Learning Disabilities (NJCLD), 116
Naturalistic, Developmental Behavioral Interventions (NBDI), 52
NCCN. See National Comprehensive Cancer Network
NCDS. See Major and Mild Neurocognitive Disorders
ND-PAE. See neurobehavioral disorder associated with prenatal alcohol exposure
neonates. See infants and children; low birth weight; preterm birth
neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE), 79–80
neuroimaging. See also functional magnetic resonance imaging for dementia, 277
neuropsychological functioning, learning skills, 253. See also perinatal stroke
new-onset epilepsy, 194
NIAAA. See National Institute on Alcohol Abuse and Alcoholism
NJCLD. See National Joint Committee on Learning Disabilities
non-verbal learning, with FASD, 86
nutrition. See diet and nutrition
obstructive sleep apnea (OSA), 249
oppositional defiant disorder (ODD), 9, 95
OSA. See obstructive sleep apnea
P.A.E. See prenatal alcohol exposure
partial fetal alcohol syndrome (pFAS), 79
PBRT. See photon beam radiation therapy
PCA. See posterior cerebral arteries
pediatric cancer. See also specific cancers
assessment strategies, 173
cogstate program, 178–179
behavioral functioning, 171–172
clinical manifestations, 166–167
cognitive rehabilitation, 179–180
clinical practice implications, 168
emotional functioning, 171–172
longitudinal outcomes, 171–172
interventions for, 173–175
cognitive, 174
educational, 174
future research on, 178, 179
online, 174–175
pharmacological, 173
socioemotional, 175
long-term effects into adulthood, 163
neuropsychological resources, 176
neuroanatomical correlates, 166–167
neuropsychological functioning with, 170–171
academic outcomes, 171
attention deficits, 170
EF, 170
general moderators of, 172
intellectual functioning, 170
memory functions, 170, 171
speed and motor functions, 170
pharmacological prevents, 169–170
psychosocial functioning, 171–172
longitudinal outcomes, 171–172
treatment strategies
chemoprotectants, 169
CRT, use limitations of, 169
hyperfractionation, 169
PBRT, 169
pediatric HIV (PHIV), 213–216
academic outcomes, 214–215
acquisition pre-birth, 211–212
adaptive functioning, 215
behavioral and emotional functioning, 215
clinical practices, 227–228
cognitive functioning, 213–215
evidence-based guidelines, 221–223
language acquisition skills, 214–215
memory deficits, 214
pediatric ischemic stroke, 244
ADHD and, 253
aphasia, 256
clinical practices, 257, 260–261
hemispatial neglect, 256
heterogeneous population for,
interventions, 256–260
language skills development, 252
learning skills, 253
memory deficits, 253
Index
for developmental issues, 37
for EF, 37
through interprofessional team partnering, with families, 36–37
through medical care, 37
for psychological functioning, 37–38
transition to adult care, 38
defined, 24
epidemiology of, 24–25
ETV/CPC and, 38–39
features, 24
HRQOL with, 29
intervention strategies, 33–37
for academic outcome success, 35
for attention deficits, 33–34
for EF, 34
for family functioning, 35–36
for functional adaptation, 36
for language skills development, 34
for memory deficits, 34–35
for motor functioning issues, 35
for psychological functioning, 35–36
for social functioning, 35–36
for visual-spatial difficulties, 35
vocational training, 37
mortality rates with, 25
neuropsychological evaluations with, 30–33
for academic outcomes, 32–33
for attention deficits, 31
brain development, 31
for EF, 31
for family functioning, 33
for functional adaptation, 33
for language skills, 31–32
for memory, 32
for motor functioning, 32
for psychological functioning, 33
for social functioning, 33
for visual-spatial abilities, 32
pathophysiology, 24–25
Chiari-II malformation in, 25
hydrocephalus in, 25
non-genetic factors, 25
prevalence rates, by race, 24
prevention strategies, 25
tectal beaking and, 26
stroke. See also pediatric ischemic stroke
cerebral atrophy, 254
clinical practices, 260–261
CSVD, 247, 248, 254
definitions, 244, 245
depression and, 262
diet and, 249
Flair MRI, 247–248
hemorrhagic, 244
AVM and, 247
risk factors, 247
incidence rates, 244
intervention strategies, 258–260
rt-PA therapy, 258
ischemic, 188
CSVT, 244
MCA and, 254
neuropsychological functioning, 250–258
cognitive functions, 257–258,
263–263
EF, 257–257
lesion location and, 254
memory deficits, 257
post-stroke, 262–263
OSA and, 249
prevention strategies, 248–250,
258–260
cholesterol level management, 249
diabetes management, 249
through lifestyle modification,
249–250
through medical management,
249
risk factors, 244, 259–259
atrial fibrillation, 249
SBD and, 249
types, 245
VCI and, 263–263
Sunitinib, 173–174
tamoxifen, 167–168
TBI. See traumatic brain injury
tectal beaking, 26
teriflunomide, 237
Theory of Visual Attention (TVA), 31
top-down attentional abilities, 26
topiramate, 168–169
training. See behavioral parent
training; facilitative intervention training;
vocational training
translocation trisomy, 64–65
traumatic brain injury (TBI)
behavioral and emotional outcomes with,
144–145
in adolescents, 145
in children, 144–145
blast injuries and, 140–141
clinical manifestations of, 141–142
mild TBI, 142
mortality rates with, 33
targets, 249
vocational training, 29
traumatic stroke
behavioral and emotional outcomes
with, 144–145
mild TBI, 142
moderate-severe TBI, 142
neuroanatomical correlates, 141
neurobehavioral characteristics, 141
over time, 143
cognitive outcomes with, 141,
142–144
DAI, 140
definitions, 139
severi in, 139
dementia risks, 146–147
CME, 146–147
difuse, 140
epidemiology, 139
epilepsy after, 187–188
focal, 140
functional outcomes, 145
future research on, 154–155
intellectual disability from,
63, 64
intervention strategies, 149–154
for mild TBI, 150–151
moderate-severe TBI, 151–153
return-to-school guidelines, for
children, 150–151
mild, 139, 140
assessment following, 147
clinical characteristics, 142
clinical implications, 153–154
intervention strategies, 150–151
moderate-severe, 142
AIM program, 152–153
assessment following, 147–148
clinical implications, 154
intervention strategies, 151–153
pharmacological interventions for,
153
pathophysiology, 140–141
pediatric. See also mild TBI;
mild TBI
moderate-severe TBI
adult outcomes from, 145–146
behavioral and emotional
outcomes, 144–145
clinical implications, 153–154
psychosocial outcomes, 145
return-to-school guidelines with,
150–151
prevention strategies, 148–149
psychosocial outcomes, 145
for children, 145
for families, 145
PTA and, 139, 142–143, 147
PTSD and, 144–145
treatment strategies, 149–150
trisomy 21, 64
UNAIDS. See Joint United Nations
Programme on HIV/AIDS
unexpected underachievement,
learning disabilities and, 130–131
universal prevention programs
(UPPSs), 81
vagal nerve stimulator (VNS), 202
vascular cognitive impairment (VCI), 263–263
verbal learning, with FASD, 85
very low birth weight (VLBW), 2
very preterm (VP) birth, 2
visual-spatial abilities with FASD, 85
LBW/preterm birth and, 7
with pediatric ischemic stroke, 252–253
with SBM, 27–28
intervention strategies for, 35
neuropsychological evaluations of, 32
VLBW. See very low birth weight
VNS. See vagal nerve stimulator
vocational training, as SBM intervention strategy, 37
VP birth. See very preterm birth
Wechsler Intelligence Scale for Children (WISC-V), 31
Wechsler Preschool and Primary Scale of Intelligence, Revised (WPPSI-R), 12
white matter development, with megencephaly, 48
WHO. See World Health Organization
Williams syndrome (WS), 67–68
comorbidities, 67
epidemiology, 67
etiology, 67
life expectancy, 68
neurobehavioral profile, 68
neurological basis, 68
phenotype, 67
prevalence, 67
WISC-V. See Wechsler Intelligence Scale for Children
women. See also low birth weight; preterm birth; small for gestational age birth
ADHD and, 94
FXS and, 67
MS and, 228
Woodcock-Johnson IV Tests of Achievement, 32
working memory, 27
World Health Organization (WHO), 2
WPPSI-R. See Wechsler Preschool and Primary Scale of Intelligence, Revised
WS. See Williams syndrome